RxDoctor Payments Data

Marcus Zervos, MD

Infectious Disease · Detroit, MINPI 1780752220

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $20,880 of the $25,918 with a category attached, or 80.6%. Merck accounts for 94.9% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $25,261, more than ten times the $199 reported in 2019. Among infectious disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,918in general payments, 2019–2025

Across 43 payments — averaging $602.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$25K
  • Biomerieux Inc$448
  • Melinta Therapeutics, LLC$233
  • Shionogi Inc$177
  • Astellas Pharma US Inc$162
  • AbbVie$118
  • plus $191 from 5 others
$23,465,112in research payments, 2019–2025

Across 566 payments — averaging $41,458 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$14.8M
  • Janssen Research & Development, LLC$7.8M
  • Pfizer$463K
  • Merck$169K
  • GSK$90K
  • Melinta Therapeutics, LLC$49K
  • plus $59K from 3 others

What the payments were for

  • Speaking & faculty fees$20,88081%
  • Travel & lodging$3,34713%
  • Food & beverage$1,3115%
  • Education$3801%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck20$24,590
Biomerieux Inc3$448
Melinta Therapeutics, LLC2$233
Shionogi Inc3$177
Astellas Pharma US Inc3$162
AbbVie(2 entities)5$118
Amgen2$58
Surgenex LLC1$45
Insmed, Inc.2$41
Genentech, Inc.1$25
Pfizer1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,918 in reported general payments places this provider in the 95th percentile of 257 infectious disease providers in Michigan.

See all infectious disease providers in Michigan

Medicare billing

Part B allowed, 2024
$30,176
Medicare patients
122
Services billed
290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →